Zacks Investment Research
12 Oct 2026, 16:55 UTC · 1h ago
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
Impact · against what's priced in
The clinical data and regulatory timeline for rezatapopt are positive but appear to be the primary drivers of the stock's recent 19% gain, suggesting these milestones are already reflected in the current valuation. While the efficacy in ovarian cancer is strong, the market is awaiting the Q4 2026 data updates for other cancer cohorts to expand the addressable market.
- PMVP+0.10
No priced-in read yet
- In context
The 46% overall response rate and the planned Q1 2027 NDA submission provide a clear path to commercialization, though much of this progress has already fueled a 19% price increase over three months.
Read from the article alone
Search tags
